These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2719737)

  • 1. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
    Werner RG; Langlouis-Gau H
    Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of biotechnological production processes.
    Werner RG; Langlouis-Gau H; Walz F; Allgaier H; Hoffmann H
    Arzneimittelforschung; 1988 Jun; 38(6):855-62. PubMed ID: 3052464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful development of recombinant DNA-derived pharmaceuticals.
    Werner RG; Pommer CH
    Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency and stability of recombinant fermentations.
    Wiebe ME; Builder SE
    Dev Biol Stand; 1994; 83():45-54. PubMed ID: 7883099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic stability of rDNA production systems, a case report.
    Chiu YY
    Dev Biol Stand; 1994; 83():93-7. PubMed ID: 7883104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presentation of the EEC directive (81/852)--quality.
    Lee AM
    Dev Biol Stand; 1992; 79():39-41. PubMed ID: 1286763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of therapeutic goods produced by recombinant DNA technology.
    Breschkin A
    Dev Biol Stand; 1987; 67():207-11. PubMed ID: 3475226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality assurance of products manufactured by recombinant DNA technology. Introduction and elements of a philosophy.
    van Noordwijk J
    Arzneimittelforschung; 1988 Jul; 38(7):943-7. PubMed ID: 3207439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of fermentation process for rDNA products.
    Cossar D
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):756-9. PubMed ID: 11899615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry perspective on the validation of column-based separation processes for the purification of proteins. Parenteral Drug Association.
    J Parenter Sci Technol; 1992; 46(3):87-97. PubMed ID: 1522447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
    Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
    J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fermentation on product consistency.
    Lubiniecki AS; Anumula K; Callaway J; L'Italien J; Oka M; Okita B; Wasserman G; Zabriskie D; Arathoon R; Builder S
    Dev Biol Stand; 1992; 76():105-15. PubMed ID: 1478331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian cell cultures. Part II: Genetic engineering, protein glycosylation, fermentation and process control.
    Werner RG; Noé W
    Arzneimittelforschung; 1993 Nov; 43(11):1242-9. PubMed ID: 8292072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-cell density cultivation of recombinant Escherichia coli for production of TRAIL by using a 2-stage feeding strategy].
    Zhang Y; Shen YL; Xia XX; Sun AY; Wei DZ; Zhou JS; Zhang GJ; Wang LH; Jiao BH
    Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):408-13. PubMed ID: 15971615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and phenotypic markers and their relationship to product quality and consistency.
    Adamson SR; Charlebois TS
    Dev Biol Stand; 1994; 83():31-44. PubMed ID: 7883098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tobramycin impurities for quality control process monitoring using high-performance anion-exchange chromatography with integrated pulsed amperometric detection.
    Hanko VP; Rohrer JS; Liu HH; Zheng C; Zhang S; Liu X; Tang X
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):828-33. PubMed ID: 18486398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.